

Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

This patient input submission was completed with the input and participation solely from staff and directors of Kidney Cancer Canada.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

Survey design, and data analysis was completed solely by staff and directors of Kidney Cancer Canada. Survey dissemination was completed through use of Kidney Cancer Canada email lists, social media (Facebook/Twitter) and through posting of the survey link on various patient discussion forums. Kidney Cancer Canada also requested that physician members of the Kidney Cancer Research Network of Canada share the link with their patients with RCC.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
BMS
Pfizer
Novartis
Hoffman La Roche
Ipsen
Merck

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Stephen Andrew
Position: Executive Director
Patient Group: Kidney Cancer Canada
Date: August 16, 2019